Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Garbers

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 12, 2025
No evidence for paradoxical effects of tocilizumab in rodentsChristoph Garbers
The Journal of Allergy and Clinical Immunology|September 28, 2024
Important molecular differences between therapeutic IL-6 receptor inhibition and its genetic mimicry in patients with ADChristoph Garbers, Thomas Werfel
FEBS Letters|November 15, 2021
Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10Juliane Lokau, Christoph Garbers
Advances in Protein Chemistry and Structural Biology|May 1, 2019
Activating mutations of the gp130/JAK/STAT pathway in human diseasesJuliane Lokau, Christoph Garbers
The Journal of Biological Chemistry|March 11, 2018
The length of the interleukin-11 receptor stalk determines its capacity for classic signalingJuliane Lokau, Christoph Garbers
Biological Chemistry|June 7, 2013
Interleukin-6 and interleukin-11: same same but differentChristoph Garbers, Jürgen Scheller
Expert Opinion on Therapeutic Targets|January 13, 2024
Cytokines of the interleukin-6 family as emerging targets in inflammatory bowel diseaseChristoph Garbers, Juliane Lokau
Cytokine & Growth Factor Reviews|May 11, 2020
Biological functions and therapeutic opportunities of soluble cytokine receptorsJuliane Lokau, Christoph Garbers
The Lancet. Rheumatology|February 1, 2021
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19Christoph Garbers, Stefan Rose-John
Eclinicalmedicine|May 13, 2020
Soluble interleukin-6 receptor in patients with <i>JAK2</i>V617F somatic mutation and myeloproliferative neoplasmChristoph Garbers, Stefan Rose-John
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Naunyn-Schmiedeberg'S Archives of Pharmacology|March 12, 2025
No evidence for paradoxical effects of tocilizumab in rodentsChristoph Garbers
The Journal of Allergy and Clinical Immunology|September 28, 2024
Important molecular differences between therapeutic IL-6 receptor inhibition and its genetic mimicry in patients with ADChristoph Garbers, Thomas Werfel
FEBS Letters|November 15, 2021
Interleukin-6-interleukin-11 receptor chimeras reveal ionomycin-induced proteolysis beyond ADAM10Juliane Lokau, Christoph Garbers
Advances in Protein Chemistry and Structural Biology|May 1, 2019
Activating mutations of the gp130/JAK/STAT pathway in human diseasesJuliane Lokau, Christoph Garbers
The Journal of Biological Chemistry|March 11, 2018
The length of the interleukin-11 receptor stalk determines its capacity for classic signalingJuliane Lokau, Christoph Garbers
Biological Chemistry|June 7, 2013
Interleukin-6 and interleukin-11: same same but differentChristoph Garbers, Jürgen Scheller
Expert Opinion on Therapeutic Targets|January 13, 2024
Cytokines of the interleukin-6 family as emerging targets in inflammatory bowel diseaseChristoph Garbers, Juliane Lokau
Cytokine & Growth Factor Reviews|May 11, 2020
Biological functions and therapeutic opportunities of soluble cytokine receptorsJuliane Lokau, Christoph Garbers
The Lancet. Rheumatology|February 1, 2021
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19Christoph Garbers, Stefan Rose-John
Eclinicalmedicine|May 13, 2020
Soluble interleukin-6 receptor in patients with <i>JAK2</i>V617F somatic mutation and myeloproliferative neoplasmChristoph Garbers, Stefan Rose-John
Pageof 14